Navigation Links
Nucletron and Advanced Radiation Therapy (ART) Jointly Announce a Global, Strategic Partnership to Offer AccuBoost(R) for Image-Guided Breast Irradiation
Date:2/12/2009

COLUMBIA, Maryland and BILLERICA, Massachusetts, February 12 /PRNewswire/ --

- Pay-Per-Patient Pricing Available to Reduce Start-Up Barriers for Cancer Centers

Nucletron, a knowledge-based leader in radiation oncology, and Advanced Radiation Therapy (ART) announced today an exclusive global, strategic partnership to offer the AccuBoost(R) system with the microSelectron(R) high- dose rate (HDR) brachytherapy afterloader treatment delivery solution for the treatment of breast cancer. The partnership will enable clinicians all over the world to deliver boost brachytherapy as part of the whole breast irradiation procedure, providing a superior treatment option with the ultimate goal of improving clinical outcome.

The partnership offers radiation oncology centers the opportunity to implement ART's innovative technology in image-guided HDR breast brachytherapy on a pay-per-patient pricing model, along with a full complement of Nucletron's treatment planning, treatment delivery, training, licensing, reimbursement, and customized service support. ART's expansion of AccuBoost technology through its global partnership with Nucletron will further reduce the barriers to adoption of brachytherapy for cancer centers previously deterred by the initial start-up costs usually associated with implementing a breast brachytherapy program.

"We are thrilled to partner with ART and expand the availability and utilization of HDR brachytherapy globally," said Jos Lamers, chief executive officer for Nucletron. "Using Nucletron's microSelectron Digital afterloader to deliver AccuBoost technology further reduces the financial, operational, and clinical barriers many cancer centers encounter in providing brachytherapy to their patients. In conjunction with this announcement, Nucletron is offering a pay-per-patient pricing model for centers bundling the AccuBoost treatment option with their new HDR brachytherapy program, allowing these centers to pay for the service when the boost treatment is delivered, providing a more attractive financing model while delivering more treatment options to their patients."

"Advanced Radiation Therapy is pleased to partner with Nucletron," stated Piran Sioshansi, Ph.D., president and chief executive officer of ART. "Our goal is to make the AccuBoost treatment option available to as many women as possible, all over the world. The market reach and expertise in HDR brachytherapy provided by Nucletron will help us realize this goal. Together we can accelerate the introduction of this new, non-invasive, image-guided procedure to more clinical sites worldwide."

Clinical reports indicate that patients with early stage breast cancer have the best outcomes when the breast conserving lumpectomy procedure is combined with a full course of whole breast irradiation and partial breast boost dose. ART's AccuBoost combines a mammography procedure for real-time image guidance to accurately target the boost dose, and precise dose delivery by Nucletron's microSelectron family of HDR afterloaders. By increasing the accuracy of the dose-targeting and reducing the unintentional exposure to healthy tissue, including the heart, lungs, and skin, AccuBoost is expected to improve patient outcomes, minimizes side effects and result in a better cosmetic results.

Representatives will be on hand to discuss this strategic partnership at the American Brachytherapy Society's School of Breast Brachytherapy and Brachytherapy Physics in San Antonio, TX on February 12-13, and the 2009 ACRO Annual Meeting in Las Vegas, NV on February 26-27.

About Nucletron

Nucletron is a knowledge-based leader in Radiation Oncology, working with clinical teams to realize innovative solutions that improve patient care. Nucletron strives to offer the best possible choice of radiation modalities through integrated products, software and services. Critical to the Nucletron philosophy is the establishment of close working relationships with individual clinical teams - reconfiguring traditional boundaries between customer and solution provider. Many Nucletron employees have clinical experience delivering oncology care, providing an in-depth understanding of the complex needs of clinicians. For more information, visit http://www.nucletron.com.

About Advanced Radiation Therapy (ART)

ART is a women's health company dedicated to the advancement of partial breast irradiation with the goal of reducing the cancer recurrence rate and minimizing radiation related complications. ART's AccuBoost system combines real-time, image-guidance with non-invasive, high-dose rate brachytherapy to deliver a focused dose to the lumpectomy site. The AccuBoost technology is based on the premise that the best method to immobilize, image and target breast tissue is via mammography. As such, AccuBoost gives the clinicians the comfort and confidence to "see what you treat and treat what you see" and significantly reduces the unintentional exposure to the patient's heart and lungs. For more information, visit http://www.AccuBoost.com.


'/>"/>
SOURCE Nucletron B V
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Nucletron Announces Management Buy-Out to More Effectively Meet the Demands of Its Customers and the Radiation Therapy Community
2. Study finds race and ethnicity affect use of hospice services among patients with advanced cancer
3. Advanced Wound Technologies Mid-Atlantic, Inc. Announces Name Change and Reverse Stock Split
4. Abbott Acquisition of Advanced Medical Optics Clears U.S. Antitrust Review
5. ATi Tailored BI and Advanced Predictive Analytics Solutions Improve Marketing Response Rates
6. GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer
7. Abbott to Commence Tender Offer on Jan. 27 for All Outstanding Shares of Advanced Medical Optics, Inc.
8. Video: Solta Medical Introduces Advanced Thermage Body Tip 16.0 for Faster Body Shaping and Contouring Treatments
9. Estonian Cancer Patients Have Access to More Conformal Radiotherapy Treatments for First Time with Unveiling of Advanced Varian Treatment Machine
10. The Quantum Group and IBM Announce Hosting Agreement for Advanced Healthcare Solutions
11. Smith & Nephew Advanced Wound Management Comments on Temporary Injunction in United Kingdom
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/27/2016)... Park, KS (PRWEB) , ... June 27, 2016 , ... ... in retailers of Eyeglasses . , Millions of individuals in the United States ... eyeglasses have become a way to both correct vision and make a fashion statement. ...
(Date:6/26/2016)... Battle Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... abuse, joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table ... held in honor of the city’s history as home to some of the world’s ...
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
Breaking Medicine Technology: